Evidence map›Paper›PMID 36709314›Full record

ArticleHereditary cancer in clinical practice2023

Germline heterozygous exons 8-11 pathogenic BARD1 gene deletion reported for the first time in a family with suspicion of a hereditary colorectal cancer syndrome: more than an incidental finding?

Sergio Carrera, Ana Belén Rodríguez-Martínez, Intza Garin, Esther Sarasola, Cristina Martínez, Hiart Maortua, Almudena Callejo, Abigail Ruiz de Lobera, Alberto Muñoz, Nagore Miñambres and 1 more

Open access · goldAbstract read
In one paragraph

Article in Hereditary cancer in clinical practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Case Report:Frontiers in oncology · 2026
    Article
  2. GermlineCancers · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sergio CarreraHereditary Cancer Genetic Counseling Unit- Medical Oncology Department, Cruces University Hospital, Plaza de Cruces S/N. 48903, Baracaldo, Bizkaia, Spain. sergio.carrerarevilla@osakidetza.eus.
Ana Belén Rodríguez-MartínezMolecular Genetics Laboratory, Basurto University Hospital, Bilbao, Spain.
Intza GarinMolecular Genetics Laboratory, Cruces University Hospital, Baracaldo, Spain.
Esther SarasolaMolecular Genetics Laboratory, Basurto University Hospital, Bilbao, Spain.
Cristina MartínezMolecular Genetics Laboratory, Cruces University Hospital, Baracaldo, Spain.
Hiart MaortuaMolecular Genetics Laboratory, Cruces University Hospital, Baracaldo, Spain.
Almudena CallejoMedical Oncology Department, Cruces University Hospital, Baracaldo, Spain.
Abigail Ruiz de LoberaMedical Oncology Department, Cruces University Hospital, Baracaldo, Spain.
Alberto MuñozMedical Oncology Department, Cruces University Hospital, Baracaldo, Spain.
Nagore MiñambresMedical Oncology Department, Cruces University Hospital, Baracaldo, Spain.
Pablo Jiménez-LabaigMedical Oncology Department, Cruces University Hospital, Baracaldo, Spain.
Hospital de Cruces · ESHospital de Basurto · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is a highly prevalent disease in developed countries. Inherited Mendelian causes account for approximately 5% of CRC cases, with Lynch syndrome and familial adenomatous polyposis being the most prevalent forms. Scientific efforts are focused on the discovery of new candidate genes associated with CRC and new associations of phenotypes with well-established cancer-related genes. BRCA1-associated ring domain (BARD1) gene deleterious germline variants are associated with a moderate increase in the relative risk of breast cancer, but their association with other neoplasms, such as CRC, remains unclear. CASE PRESENTATION: We present the case of a 49-year-old male diagnosed with rectal adenocarcinoma whose maternal family fulfilled Amsterdam clinical criteria for Lynch syndrome. Genetic test confirmed the presence in heterozygosis of a germline pathogenic deletion of exons 8-11 in BARD1 gene. The predictive genetic study of the family revealed the presence of this pathogenic variant in his deceased cancer affected relatives, confirming co-segregation of the deletion with the disease.

conclusionsTo the best of our knowledge, this is the first published work in which this BARD1 deletion is detected in a family with familial colorectal cancer type X (FCCTX) syndrome, in which the clinical criteria for Lynch syndrome without alteration of the DNA mismatch repair (MMR) system are fulfilled. Whether this incidental germline finding is the cause of familial colorectal aggregation remains to be elucidated in scientific forums. Patients should be carefully assessed in specific cancer genetic counseling units to account for hypothetical casual findings in other genes, in principle unrelated to the initial clinical suspicion, but with potential impact on their health.

Indexed as

Amsterdam clinical criteriaBARD1Cancer genetic counselingColorectal cancerDeletionFamilial colorectal cancer type X syndromeHereditaryPathogenic variant

Identifiers

PMID36709314
PMCPMC9883939
OpenAlexW4318318078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.